Tower Research Capital LLC (Trc) Larimar Therapeutics, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $4.87 Billion
- Q4 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 2,850 shares of LRMR stock, worth $9,376. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,850
Previous 1,452
96.28%
Holding current value
$9,376
Previous $9,000
11.11%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding LRMR
# of Institutions
125Shares Held
67.1MCall Options Held
505KPut Options Held
76.3K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$69.9 Million2.59% of portfolio
-
Janus Henderson Group PLC London, X06.44MShares$21.2 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$19.9 Million0.55% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.65MShares$15.3 Million7.6% of portfolio
-
Goldman Sachs Group Inc New York, NY4.15MShares$13.7 Million0.0% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $142M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...